No. 21-757October Term 2022Decided May 18, 2023
Amgen Inc. v. Sanofi
In a unanimous decision, the Supreme Court ruled that two of Amgen's patents for cholesterol-lowering drugs were invalid because they were too broad.
Case status
- Current stage
- Decided
- Latest event
- Decision released May 18, 2023
- What it's about
In a unanimous decision, the Supreme Court ruled that two of Amgen's patents for cholesterol-lowering drugs were invalid because they were too broad. The Court found the patents failed to satisfy the Patent Act's enablement clause by claiming an entire class of antibodies without providing enough detail for a skilled person to make and use them.
Question presented
Whether the standard for determining the adequacy of the "written description of the invention" in a patent must be "in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains . ."?
- Case path
United States Court of Appeals for the Federal Circuit / Decision released May 18, 2023
- Area
Decided Supreme Court case
Documents
Related cases
Grounding
- Grounding
- Primary-source trail available.
- Note
- Plain-English explainer. Official filings and opinions remain authoritative.
- Checked
- Mar 30, 2026
- Method
- Methodology